PRKAA2 and diabetes mellitus: In this report, we have described in detail the effects of treatment with R419, a novel small molecule that inhibits complex I, resulting in potent stimulation of AMPK activity in vitro and in vivo, and have characterized its effects both in cell lines and in a mouse model of diabetes.